AbCellera Biologics Inc. (ABCL) Stock Forecast
ABCL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 12 analysts
- Price target
- $16.82 average of analyst targets
- Upside to target
- +42.5% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.18
- 52-week range
- $2.78 – $14.82
ABCL analyst ratings
12 analystsNumber of analysts at each rating.
ABCL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ABCL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.20 | −$0.16 | −$0.19 | +6.5% | 6 |
| Current fiscal year (2026) | −$0.67 | −$0.73 | −$0.63 | −$0.49 | −37.6% | 8 |
| Next fiscal year (2027) | −$0.76 | −$0.96 | −$0.56 | −$0.67 | −13.1% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ABCL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.2M | $3.0M | $15.6M | −30.2% | 10 |
| Current fiscal year (2026) | $26.4M | $18.0M | $43.6M | −64.9% | 11 |
| Next fiscal year (2027) | $28.2M | $6.6M | $62.9M | +7.1% | 10 |
ABCL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ABCL revenue: reported and forecast
ABCL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.17 | −$0.17 | −$0.18 | −$0.18 | +1.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.65 | −$0.66 | −$0.66 | −$0.68 | −$0.67 | +3.7% | 1 up · 3 down |
| Next fiscal year (2027) | −$0.72 | −$0.71 | −$0.71 | −$0.78 | −$0.76 | +5.9% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ABCL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ABCL beat in 7 of 12.
What analysts expect from ABCL
12 analysts cover AbCellera Biologics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $16.82, 42.5% above the latest close of $11.80. Analysts expect earnings of −$0.67 per share for 2026, −37.6% from a year earlier. For 2027 the average estimate is −$0.76 per share on revenue of $28.2 million. AbCellera Biologics beat the EPS estimate in 7 of the last 12 quarters.
Related: ABCL income statement, ABCL key metrics, ABCL chart. See the ABCL stock overview for the latest quote and news.
ABCL forecast FAQ
What is AbCellera Biologics's price target?
The average analyst price target for AbCellera Biologics is $16.82, 42.5% above the latest close of $11.80.
Is AbCellera Biologics a buy, hold or sell?
Of 12 analysts covering AbCellera Biologics, 9 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AbCellera Biologics's EPS forecast?
Analysts forecast −$0.67 per share for 2026 (range −$0.73 to −$0.63); for 2027 the estimate is −$0.76.
What is AbCellera Biologics's revenue forecast?
The average revenue estimate for 2026 is $26.4 million, growth of −64.9%; for 2027 it is $28.2 million.
When does AbCellera Biologics report earnings?
AbCellera Biologics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.18.
Does AbCellera Biologics usually beat earnings estimates?
AbCellera Biologics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.